Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia

Anxiety

Volumn 1, Issue 5, 1994, Pages 216-223

  Tancer, Manuel E ^a   Mailman, Richard B ^a,b   Stein, Murray B ^c   Mason, George A ^a   Carson, Stanley W ^a   Golden, Robert N ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b School of Medicine

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

dopamine; noradrenergic system; pharmacologic challenge; serotonin; social phobia

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; HUMAN GROWTH HORMONE; HYDROCORTISONE; LEVODOPA; NORADRENALIN; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BLINKING; BLOOD; BRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHOBIA; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-AGONISTS; ADULT; BLINKING; BRAIN; CLONIDINE; DOPAMINE; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FENFLURAMINE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; LEVODOPA; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PHOBIC DISORDERS; PROLACTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0028677299     PISSN: 10709797     EISSN: 15227154     Source Type: Journal    
DOI: 10.1002/anxi.3070010505     Document Type: Article

References (52)

1. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamic‐pituitary‐adrenocortical axis in conscious rats
2. An inventory for measuring depression
3. Fluoxetine for the Treatment of Social Phobia
4. Neuroendocrine responses to m‐chlorophenylpiperazine and 1‐tryptophan in bulimia
5. L‐tryptophan and prolactin release: Evidence for interaction between 5‐HT1 and 5‐HT2 receptors
6. Abnormal regulation of norad‐renergic function in panic disorders: Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder
7. Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior
8. Treatment of social phobia with clonazepam and placebo
9. Reliability of DSM‐III‐R anxiety disorder categories: Using the Anxiety Disorders Interview Schedule‐Revised (ADIS‐R)
10. The human growth hormone response to clonidine: Relationship to clinical and neuroendocrine profile in depression
11. Pharmacotherapy versus cognitive therapy for the treatment of social phobia
12. An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder
13. Growth‐hormone and prolactin response to levodopa in affective illness
14. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine response to meta‐chloro‐phenylpiperazine in obsessive compulsive disorder
15. Serotonergic function in obsessive‐compulsive disorder. Behavioral and neuroendocrine responses to oral m‐chlorophenylpiperazine and fenfluramine in patients and healthy volunteers
16. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder
17. Spontaneous eye‐blink rates and dopaminergic systems
18. Lifetime and 12‐month prevalence of DSM‐III‐R psychiatric disorders in the United States: Results from the National Comorbidity Survey
19. Responses of “generalized” and “discrete” social phobics during public speaking
20. Effects of oral clonidine on plasma 3‐methoxy‐4‐hydroxyphenylethyl‐eneglycol (MHPG) in man: Preliminary report
21. Social phobia: A review of a neglected anxiety disorder
22. MAOIs: Impact on social behavior
23. Phenelzine vs atenolol in social phobia: A placebo‐controlled comparison
24. Prolactin and growth hormone response to levodopa in affective illness
25. Brief standard self‐rating for phobic patients
26. Neuroendocrine and behavioral response to challenge with the indirect serotonin agonist dl‐fenfluramine in adults with obsessive‐compulsive disorder
27. Hormonal responses to fenfluramine in depressive subtypes
28. Effect of diet on urinary MHPG excretion in depressed patients and normal control subjects
29. Four types of social phobia in a community sample
30. Social phobia: Comorbidity and morbidity in an epidemiologic sample
31. Fluoxetine in social phobia
32. 2‐adrenergic agonist clonidine
33. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central seroto‐nergic responsivity in depression
34. Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders: Comparison of patients with panic disorder, social phobia, and healthy controls
35. Lymphocyte β‐adreno‐ceptors in social phobia
36. Setting diagnostic thresholds for social phobia: Considerations from a community survey of social anxiety
37. Autonomic responsivity in generalized social phobia
38. 3H]paroxetine binding in social phobia: Comparison to patients with panic disorder and healthy volunteers
39. Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers
40. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder
41. Fenfluramine provocation of anxiety in patients with panic disorder
42. Blunted growth hormone response to clonidine in panic disorder patients
43. Fluoxetine in efficacy social phobia
44. Sero‐tonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothala‐mus
45. Hormonal probes of central serotonergic activity: Do they really exist?
46. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
47. Measurement of social‐evaluative anxiety
48. Serotonergic responsivity in obsessive‐compulsive disorder: Effects of chronic clomipramine treatment